# Who are Tempus AI's customers? Who does Tempus AI earn revenue from?
Canonical: https://valuechain.wiki/tempus-ai · Facet: customers · Updated: 2026-07-12T04:00:27.732593+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Tempus AI discloses no named confirmed revenue counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 revenue edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-07-12).

### 병원·진단 (종양 유전자검사) (high)
- note: Oncology DNA/RNA and liquid-biopsy testing to hospitals (75% of revenue).
- [confirms] Tempus (EN, filing, published 2026-02-24) https://www.tempus.com/news/pr/tempus-reports-fourth-quarter-and-full-year-2025-results/: "Oncology DNA/RNA and liquid-biopsy testing to hospitals (75% of revenue)."
- [confirms] Seeking Alpha (EN, research, published 2026-01-01) https://seekingalpha.com/article/4854303-tempus-ai-a-healthcare-hyper-growth-opportunity-for-the-risk-tolerant: "Oncology DNA/RNA and liquid-biopsy testing to hospitals (75% of revenue)."

### 제약 (AZ·파토스 데이터·파운데이션 모델) (high)
- note: Data licensing and foundation-model fees ($200M) to pharma like AstraZeneca and Pathos.
- [confirms] Tempus (EN, filing, published 2026-02-24) https://www.tempus.com/news/pr/tempus-reports-fourth-quarter-and-full-year-2025-results/: "Data licensing and foundation-model fees ($200M) to pharma like AstraZeneca and Pathos."
- [confirms] Yahoo Finance (EN, news, published 2026-01-01) https://finance.yahoo.com/sectors/healthcare/articles/tempus-ais-diagnostics-data-arms-160300587.html: "Data licensing and foundation-model fees ($200M) to pharma like AstraZeneca and Pathos."

Reverse side: https://valuechain.wiki/tempus-ai/suppliers.md · Ripple: https://valuechain.wiki/tempus-ai/ripple.md

---
Full node: https://valuechain.wiki/tempus-ai.md · JSON: https://valuechain.wiki/tempus-ai.json